Replies to post #254098 on Biotech Values

[WorstLuck]

I don't think there is anything in the advanced Enanta pipeline that is worthy of an acquisition

I agree. There is some chance that RSV pans out. It feels more likely that they run another P2 (or two) with 323/combo before giving up. There are shots on goal but...

As pointed out, the solution is to simply not invest. The problem for me, as well as a lot of other people, is that we're already invested in what seemed like a decent investment with recurring revenue and multiple shots on goal most of which have now fallen by the wayside.

If you weren't already an investor, would you buy at these levels? I understand there are tax implications and so on... but it's a good question to ask.

What I think Jay Luly lacks is a vision

I think his vision just doesn't match up well with my views as an investor. The strategic approach is another thing I don't like as an investor. For someone else they may be fine.

Thanks for the thoughtful views. Understanding where someone else stands is a big thing.

[DewDiligence]

So shareholders have a choice of doing nothing and hoping for the best or convincing the company to make changes.

I don't know how ordinary shareholders can persuade a company to change direction. However, for the sake of discussion let's say that you were a member of ENTA's BoD. What specific changes would you seek now? TIA

[DewDiligence]

…I don't think there is anything in the advanced Enanta pipeline that is worthy of an acquisition…

Respectfully disagree on this point.

Moreover, at the current valuation ENTA could receive buyout interest from a company who had little or no interest in ENTA’s pipeline and merely wanted to raise capital cheaply.

[alertmeipp]

Interesting take on ENTAs pipeline.

Pretty much all analyst reports I read are quite pleased with ENTAs RSV program, mostly see it as first and best in class.

I think that program alone would be quite attractive for acquirers. A few pharmaceutical are working on RSV area. They not only care about they want, they also need to make sure the other RSV competitors don’t get the potentially best asset in the field.

Not sure about the CEO, but it seems to me the weakest link in ENTA is its business development and partnerships department. Maybe they are too greedy and always want bigger pie by running the program as far as they can themselves and end up stuck with nothing but a big hole in expenses.